Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis [FT.com - Mergermarket]
Janus Henderson Group plc Ordinary Shares (JHG)
Last janus henderson group plc ordinary shares earnings: 4/30 04:00 am
Check Earnings Report
US:NYSE Investor Relations:
snl.com/irw/corporateprofile/4147331
Company Research
Source: FT.com - Mergermarket
Oliver BarnesJump to comments sectionStay informed with free updatesSimply sign up to the Digest -- delivered directly to your inbox.So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years. As such, it is not cheap: in the , it costs $300,000 per patient, per year. But given the transformative nature of the treatment for a disease with a poor prognosis, the high list price has not held back sales for the pharma group.And, now, the same team of scientists at Vertex’s San Diego laboratory have a second decades-long research project coming to fruition that could unlock another potentially huge market: non-opioid painkillers.If patients live longer, “it’s good for business”, says David Altshuler, Vertex’s chief scientific officer. The number of people living with CF worldwide is now 105,000, up from 70,000 in 2012, according to estimates from no
Show less
Read more
Impact Snapshot
Event Time:
JHG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JHG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JHG alerts
High impacting Janus Henderson Group plc Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JHG
News
- Janus Henderson Group plc Just Recorded A 33% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
- Janus Henderson Group plc (NYSE: JHG) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Janus Henderson Group plc (NYSE: JHG) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $36.00. They now have a "neutral" rating on the stock.MarketBeat
- Markets jump higher after softer-than-expected jobs report fuels hopes of an earlier rate cut [CNN]CNN
- JHG vs. BLK: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
JHG
Earnings
- 5/2/24 - Beat
JHG
Sec Filings
- 5/3/24 - Form 8-K
- 5/2/24 - Form 497J
- 5/2/24 - Form 10-Q
- JHG's page on the SEC website